Loading data for REVB — first visit, this takes a few seconds.
Revelation Biosciences, Inc. (REVB)
NasdaqCM: REVB
· 即時價格 · USD
1.01
-0.04 (-3.81%)
收盤價： Sep 02, 2026, 5:22 PM
股價、關鍵數字和最新消息，都在這一頁。
Revelation Biosciences, Inc.（REVB）股價、分析與資料
無可用資料
| 買價 | 0.76 |
| 市值 | 4.06M |
| 營收 (ttm) | n/a |
| 淨利（ttm） | -19.2M |
| -0.17 | |
| 27.03 | |
| 0.04 | |
| -0.35 | |
| P/B (ttm) | 0.40 |
| P/S (ttm) | 0.00 |
| 財報日期 | Nov 5, 2026 |
| 賣價 | 1.3 |
| 成交量 | 11,026 |
| 20 日平均成交量 | 46,031 |
| 開盤價 | 1.06 |
| 前收盤價 | 1.05 |
| 當日區間 | 1.02 - 1.06 |
| 52 週範圍 | 0.88 - 11.60 |
| 分析師 | n/a |
| 目標價 | n/a |
| 股利 | n/a |
| 除息日 | n/a |
關於 REVB
Revelation Biosciences, Inc. operates as a clinical-stage life science company that focuses on the rebalancing inflammation to optimize health. The company's lead product candidate is lead product candidate Gemini, a proprietary formulation platform of phosphorylated hexaacyl disaccharide (PHAD), an established Toll-like receptor 4 (TLR) agonist that works by modulating and rebalancing a dysregulated inflammatory response. It also engages in the ...
完整的公司簡介財報驚奇
Revelation Biosciences 已於 Aug 6, 2026 公布季度財報：
- 營收為 $0 低於預期 $0, 年增 NaN% 成長.
- 每股盈餘為 -0.87 低於預期 -0.04, 年增 96.90% 成長.